WORCESTER, Mass., June 22, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (Nasdaq:GNBT) today announced its participation as an exhibitor during the 70th Scientific Sessions organized by the American Diabetes Association (ADA). The annual conference will be held this year at the Orange County Convention Center's West Building in Orlando, Florida from June 25 to 29.
With more than 13,000 members of the diabetes community expected to be in attendance throughout this 5-day event, the symposium provides Generex the opportunity to reach a unique audience of diabetes researches and healthcare professionals with its comprehensive portfolio of breakthrough products for the treatment of Type I and Type II diabetes.
The recently announced outcomes and trends from the Company's flagship product, Generex Oral-lyn™, now in a Phase III pivotal study, will be a major topic of discussion at the Company's booth #559. With over 400 subjects enrolled in the study, the buccal insulin spray product has shown excellent results and compelling observations in the areas of insulin antibody levels, weight gain, body mass index, and hypoglycemic events.
"While Generex Oral-lyn™ offers a unique and proprietary insulin delivery method, it's not new science; rather, it is the coupling of insulin with a proprietary misting device that looks like an asthma-inhaler but does NOT allow the product to go to the lungs; rather it is sprayed into the mouth to allow absorption in the cheeks and oral cavity to create an environment that help patients live successfully with the disease," stated Anna Gluskin, Generex's President & Chief Executive Officer. "Insulin has been used for nearly 82 years and consequently has an excellent safety profile unlike the many new drugs that now have 15-year follow-up minimums due to the recent and unfortunate cardiac events affecting many of their patients."
MetControl™, which delivers metformin in a pleasant-tasting chewing gum that allows fast absorption, and Glucose RapidSpray™, a consumer product to be taken at the first sign of needing additional glucose in your diet will also be featured at the Company's booth.
"Our line-up of diabetes products are designed to improve the lifestyle of people with Diabetes, with solutions that allow for toxic-free ways to manage the disease at an early stage without the hassle of injections," added Gluskin.
Generex's research into diabetic foot care will also be explored in the conference's official abstract booklet available to all those who attend. "Effects Of A Loofa Scrub Soap Prepared From Dead Sea For Care Of Diabetic Foot" was authored by Daria Maggi, Emanuela Camera, Elva Abril, Mauro Picardo, Anna Rita Maurizi, Silvia Manfrini and Paolo Pozzilli, all researchers at University Campus Bio-Medico in Rome, Italy.
Senior-level executives of the Company will be available for discussion at exhibit booth #559 (open) during the following times:
- Sat. June 26 from 10:00 a.m. to 4:00 p.m. .
- Sun. June 27 from 10:00 a.m. to 4:00 p.m.
- Mon. June 28 from 10:00 a.m. to 2:00 p.m.
About Generex Biotechnology Corporation
Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, buccal insulin (Generex Oral-lyn™), which has been approved in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831
Safe Harbor Statement
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.